Cencora (COR) to Release Quarterly Earnings on Wednesday

Cencora (NYSE:COR) is anticipated to announce its Q3 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of $4.35 per share and revenue of $84.3145 billion for the quarter. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Individuals may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter in the previous year, the firm posted $4.42 earnings per share. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. On average, analysts expect Cencora to post $18 EPS for the current fiscal year and $20 EPS for the next fiscal year.

Cencora Price Performance

Shares of NYSE:COR opened at $320.05 on Wednesday. The company has a market cap of $62.27 billion, a price-to-earnings ratio of 24.54, a PEG ratio of 1.73 and a beta of 0.58. The business has a 50 day moving average price of $286.59 and a 200 day moving average price of $315.90. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. Cencora has a twelve month low of $244.82 and a twelve month high of $377.54.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio is currently 18.40%.

Cencora announced that its board has authorized a stock repurchase plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to repurchase up to 3.9% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Insider Transactions at Cencora

In other Cencora news, Director Lauren M. Tyler purchased 550 shares of the stock in a transaction on Monday, June 22nd. The shares were purchased at an average price of $270.23 per share, with a total value of $148,626.50. Following the acquisition, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This represents a 14.44% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.38% of the stock is owned by company insiders.

Institutional Trading of Cencora

Institutional investors have recently made changes to their positions in the business. Kemnay Advisory Services Inc. acquired a new position in Cencora in the fourth quarter worth about $25,000. Motiv8 Investments LLC acquired a new stake in Cencora during the fourth quarter valued at approximately $29,000. Turning Point Benefit Group Inc. bought a new stake in shares of Cencora in the 3rd quarter valued at approximately $74,000. DV Equities LLC acquired a new position in shares of Cencora in the 4th quarter worth approximately $91,000. Finally, Greenline Wealth Management LLC bought a new position in shares of Cencora during the 4th quarter worth approximately $109,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on COR. Weiss Ratings cut shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 30th. UBS Group raised their price target on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Robert W. Baird dropped their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Evercore set a $360.00 price objective on shares of Cencora in a research report on Wednesday, April 8th. Finally, Bank of America lifted their target price on Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 24th. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $367.75.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.